Gordian Biotechnologies

Gordian: first-in-class reversible beta-lactamase inhibitors that allow existing antibiotics to be effective against drug-resistant pathogens.

  • Stage Product In Development
  • Industry Biotechnology
  • Location West Palm Beach, FL, US
  • Currency USD
  • Founded January 2014
  • Employees 2
  • Website gordianbio.com

Company Summary

Gordian Biotechnologies is developing a pipeline of first-in-class reversible beta-lactamase inhibitors for the treatment of resistant bacterial infections. The company's products combine with already approved antibiotics to make them once again effective against what would otherwise be a resistant infection by attacking the bacteria's resistance mechanism.

Team

  • Tony Brazzale
    CEO

    Mr. Brazzale has over 18 years as a medicinal chemist (antibiotics and women's health) and business development professional in the life sciences and therapeutic biotechnology sector possessing international experience. He is a co-founder of Melanovus Oncology and Past Chair of the American Chemical Society Division of Business Development and Management.

  • Peter Gordon
    Interim CFO

    Mr Gordon serves as the Interim CFO of Gordian BioTechnologies, Inc. He has over 15 years of experience as a Chief Financial Officer in Biotechnology, Medical Device, Securities, E-Commerce and other industries. He also is the President of 1st U.S. Capital, Inc., a financial advisory consulting firm as well as The CFO of Melanovus Oncology, Inc.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free